Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
SEQUOIA trial: what clinicians have said so far
Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer
- NCT02923921 ↗
- Completed
- Eli Lilly and Company
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on SEQUOIA (pegilodecakin in second-line metastatic pancreatic cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SEQUOIA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Pancreatic Cancer
- Interventions
- Pegilodecakin; FOLFOX
- Arms
- Pegilodecakin + FOLFOX · Experimental
- FOLFOX · Active comparator
- Enrollment
- 567
- Primary outcomes
- Overall Survival
- Sponsor
- Eli Lilly and Company with ARMO BioSciences
- Start
- Mar 1, 2017
- Primary completion
- Sep 9, 2019
- Results posted
- Yes
- Registry record
- NCT02923921 · updated Oct 19, 2020
Publications
linked from the registry- Hecht JR, Lonardi S, Bendell J, Sim HW, Macarulla T, Lopez CD, Van Cutsem E, Munoz Martin AJ, Park JO, Greil R, Wang H, Hozak RR, Gueorguieva I, Lin Y, Rao S, Ryoo BY. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA). J Clin Oncol. 2021 Apr 1;39(10):1108-1118. doi: 10.1200/JCO.20.02232. Epub 2021 Feb 8. PubMed 33555926